Strategic Business Pivoting For Cell & Gene Startups

By I-Wen Chen

With the help of new regulatory guidelines, manufacturing process improvements, and platforms for secondary sequencing analysis, cell and gene therapy manufacturers are learning to pivot their product offerings to better meet the demands of the market and the expanding quality control regulations as the sector matures. But this market needs to find an implementing strategy that helps build a pipeline more quickly and effectively.